Cargando…
Comparison of different predictive biomarker testing assays for PD-1/PD-L1 checkpoint inhibitors response: a systematic review and network meta-analysis
BACKGROUND: Accurate prediction of efficacy of programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) checkpoint inhibitors is of critical importance. To address this issue, a network meta-analysis (NMA) comparing existing common measurements for curative effect of PD-1/PD-L1 monother...
Autores principales: | Shi, Haotong, Zhang, Wenxia, Zhang, Lin, Zheng, Yawen, Dong, Taotao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562577/ https://www.ncbi.nlm.nih.gov/pubmed/37822932 http://dx.doi.org/10.3389/fimmu.2023.1265202 |
Ejemplares similares
-
PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022) -
PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis
por: Khan, Muhammad, et al.
Publicado: (2023) -
The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
por: Tang, Qing, et al.
Publicado: (2022) -
Total neoadjuvant treatment and PD-1/PD-L1 checkpoint inhibitor in locally advanced rectal cancer
por: Xiao, Weiwei, et al.
Publicado: (2023) -
Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint
por: Gu, Tingxuan, et al.
Publicado: (2023)